# Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

> **NCT07054346** · PHASE1 · RECRUITING · sponsor: **Thomas Hope** · enrollment: 45 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer (Diagnosis)
- High-risk Prostate Cancer
- Localized Prostate Carcinoma
- Very High Risk Prostate Carcinoma

## Interventions

- **DRUG:** 177 Lutetium Prostate-Specific Membrane Antigen 617
- **DRUG:** Actinium-225 Prostate-Specific Membrane Antigen 617
- **PROCEDURE:** Non-investigational, Prostatectomy
- **PROCEDURE:** Prostate Tissue Collection
- **PROCEDURE:** Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
- **PROCEDURE:** Blood Sample Collection

## Key facts

- **NCT ID:** NCT07054346
- **Lead sponsor:** Thomas Hope
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054346, "Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07054346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*